GENETIC AND EPIGENETIC CONTRIBUTORS TO COVID-19 OUTCOMES: A COMPREHENSIVE REVIEW

Annals of Research in Oncology · Published 2026-06-01 · DOI 10.48286/aro.2026.126

Authors (5)

A. Amirkhani Namagerdi, M. Quinitiliani, S. Shani, M. Barbarino, F. Ciani

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Namagerdi, A., Quinitiliani, M., Shani, S., et al. (2026). GENETIC AND EPIGENETIC CONTRIBUTORS TO COVID-19 OUTCOMES: A COMPREHENSIVE REVIEW. Annals of Research in Oncology. https://doi.org/10.48286/aro.2026.126

Related articles

• SARCOMATOID CARCINOMA OF THE PROSTATE – RARE ENTITY WITH RARE PRESENTATION: A CASE REPORT · Annals of Research in Oncology · 2026 · Same journal
• Perspectives and innovation in pediatric psycho-oncology: research, advanced therapies, technologies and new frontiers · Annals of Research in Oncology · 2024 · Same journal
• RESPONSES DURING COGNITIVE STRESS TEST FOR AUTOMATIC PAIN ASSESSMENT IN CANCER PATIENTS · Annals of Research in Oncology · 2025 · Same journal
• GIANT RETROPERITONEUM SCHWANNOMA CAUSING IPSILATERAL HYDRONEPHROSIS: A RARE CASE REPORT · Annals of Research in Oncology · 2026 · Same journal
• TRENDS, CLINICOPATHOLOGIC FEATURES, AND MANAGEMENT OF IN SITU BREAST CANCER: INSIGHTS FROM THE NORTH ITALY CANCER REGISTRY, 2000-2023 · Annals of Research in Oncology · 2026 · Same journal
• ERBB2 VARIANTS DISTRIBUTION IN NON-SMALL CELL LUNG CANCER: AN ITALIAN REAL-WORLD EXPERIENCE · Annals of Research in Oncology · 2023 · Same journal
• Survival and mortality of kidney cancer in relation to cardiovascular diseases and treatments · Annals of Research in Oncology · 2025 · Same journal
• Aflibercept plus FOLFIRI as second-line therapy in metastatic colorectal cancer (mCRC) during pandemic COVID-19: a real-world experience · Annals of Research in Oncology · 2024 · Same journal
• ‘THEY ARE RARE, BUT THEY ARE THERE’. REPORT FROM THE GYNOCARE TRAINING SCHOOL IN SOFIA, BULGARIA (29TH JUNE-1ST JULY 2023) · Annals of Research in Oncology · 2023 · Same journal
• MORE VOICE FOR PATIENTS WITH ENDOMETRIAL CARCINOMA: esprimEndo POLICY STATEMENT · Annals of Research in Oncology · 2025 · Same journal